Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728999 | 0.96 | HRH3 (0.41) | HRH3THRBTHRABCHEACHE | |
| SCHEMBL729396 | 0.93 | AGER (0.39) | HRH3THRBTHRABCHEACHE | |
| SCHEMBL729165 | 0.90 | ROCK2 (0.38) | HRH3THRBTHRABCHEACHE | |
| SCHEMBL727606 | 0.90 | THRB (0.40) | HRH3THRBTHRABCHEACHE | |
| SCHEMBL721534 | 0.90 | HRH3 (0.43) | HRH3THRBTHRABCHEACHE | |
| SCHEMBL727953 | 0.89 | ROCK2 (0.39) | HRH3THRBTHRABCHEACHE | |
| SCHEMBL729226 | 0.89 | THRB (0.45) | HRH3THRBTHRATRPV4KDM4E | |
| SCHEMBL729286 | 0.89 | HRH3 (0.42) | HRH3THRBTHRASMN1; SMN2ROCK2 | |
| SCHEMBL727358 | 0.88 | HRH3 (0.43) | HRH3THRBTHRABCHEACHE | |
| SCHEMBL727712 | 0.87 | HRH3 (0.44) | HRH3THRBTHRABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529876-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | claimed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | claimed |
| US-20100249402-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO. LTD. (KR) | 2010-09-30 | — | — | US | claimed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | claimed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | claimed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | disclosed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | disclosed |
| US-20100249402-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO. LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249402-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME | SOST, CTSA, BECN1 | HRH3 167/4885THRB 4077/4885THRA 3946/4885 |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | SOST, BPGM, PTH1R | HRH3 64/4885THRB 2965/4885THRA 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.